Search Results

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program.

The Leukemia & Lymphoma Society®, a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced a collaboration to accelerate blood cancer research.

Tasso, Inc. today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples.

Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC) today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.

Tasso, Inc. today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program.

Tasso, Inc. today announced that the TassoOne™ Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.

Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device.

Evelo Biosciences, Inc. announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors.

Tasso, Inc., a leader in clinical-grade blood collection technology, announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.